Yahoo Canada Original Videos
Canada reacts to PM Trudeau's long pause
June 3, 2020, 7:44 p.m.
Experts and citizens try to decide what PM Trudeau was thinking when he was silent for a full 21 seconds after being asked a question about President Trump. Video by Shibani Gokhale
Barack, Bill and Dubya: How Democrats came to embrace George W Bush
Keeping quiet on politics, combined with nostalgia viewed through Trump-coloured glasses, has reformed Mr Bush's image, writes Justin Vallejo
Sibusiso Moyo: Zimbabwe foreign minister dies from Covid-19
The southern African state has recorded a surge in cases since the end of the festive season.
PA Media: Entertainment
Paloma Faith to be subject of BBC documentary about work and motherhood
The singer is pregnant with her second child.
Tiziana Life Sciences to Participate in a Fireside Chat at B. Riley Virtual Oncology Investor Conference on 21 January 2021 at 3 pm ET/8 pm GMT
NEW YORK and LONDON, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced its CEO and CSO, Dr. Kunwar Shailubhai, will participate in a fireside chat via a video link on Thursday 21 January 2021 at 3 pm ET / 8 pm GMT to provide updates on the Company. Date:Thursday 21 January 2021Time:3 pm U.S. Eastern / 8 pm GMTWebcast:https://b-riley-oncology-investor-conference.events.issuerdirect.com/signup About Tiziana Life SciencesTiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to Milciclib, the Company is also developing Foralumab for liver diseases. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients. For further enquiries: United Kingdom Investors: Tiziana Life Sciences plcGabriele Cerrone, Chairman and Founder+44 (0)20 7495 2379 United States Investors: Dave GentryRedChip Companies Inc.Office 1 800 RED CHIP (733 2447)Cell 407-491-4498 (USA)dave@redchip.com